SCHEMBL25755433

SCHEMBL25755433

O=C(O[C@@H]1[C@H](OC(=O)c2ccccc2)[C@@H]2CC[C@H]1c1ccccc12)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 3/20 0.49
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HTR3E A5X5Y0 1/20 0.46
▸ HTR3B O95264 1/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ HTR3D Q70Z44 1/20 0.46
▸ HTR3C Q8WXA8 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ APOBEC3A P31941 1/20 0.45
▸ APOBEC3G Q9HC16 1/20 0.45
▸ F2 P00734 1/20 0.45
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ CHRM2 P08172 2/20 0.43
▸ CHRM4 P08173 2/20 0.43
▸ CHRM1 P11229 2/20 0.43
▸ CHRM3 P20309 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25796899 1.00 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL25755428 1.00 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL25796905 1.00 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL27052057 0.93 CHRM2 (0.48) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL24278683 0.89 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL27053452 0.89 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL25755225 0.89 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL25796848 0.89 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL25796830 0.89 CHRNA7 (0.49) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL7154464 0.80 LMNA (0.61) CHRNA7MEN1KMT2AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067763-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed
US-20240067763-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 — — US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 — — US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 — — US disclosed
EP-4206238-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER Mitsui Chemicals, Inc. (JP) 2023-07-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025838-A1 ESTER COMPOUND NR1H3, CYP4A11, H1-4 CHRNA7 3219/4885MEN1 709/4885KMT2A 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback